Wen‐Chi Foo
Papers
1
Total Citations
10
H-Index
1
About
Wen‐Chi Foo is a pathologist whose research has significantly advanced the understanding of prostate cancer grading and its clinical implications. Her key work focuses on the critical discrepancy between biopsy and surgical pathology, particularly for high-risk disease. In her highly cited 2017 study, Foo demonstrated that over half of contemporary clinical Gleason 8 prostate cancers identified on biopsy are downgraded at radical prostatectomy. This finding challenges the assumption that a biopsy Gleason score of 8 uniformly represents high-risk disease, directly impacting treatment decisions and patient counseling. By highlighting the limitations of biopsy-based grading, Foo's research has helped refine risk stratification, preventing potential overtreatment in men whose disease is actually lower grade. Her contributions underscore the importance of integrating pathological findings with clinical context, making her work essential reading for urologists, oncologists, and pathologists. With over 10 citations on this pivotal paper alone, Foo's insights continue to shape contemporary prostate cancer management, emphasizing the need for nuanced interpretation of biopsy results in the era of precision medicine.
Research Focus
Key Achievements
Top Papers
- 1